Nanomaterial-Assisted Stem Cell-Based Therapy for Primary Osteoporosis: Challenges and Future Trends

Osteoporosis is a global health crisis affecting millions of people worldwide, and its incidence increases as a consequence of the increase in the percentage of aged people within the population. Osteoporosis-related fractures are the most prominent reasons for disability and mortality. Bone is continually remodeled to sustain its structural integrity and mineral content. Any imbalance in bone remodeling activity could lead to many bone disorders. Current therapeutic interventions in osteoporosis target resorptive and anabolic events. Although these treatment modalities aim to reduce the intensity of bone remodeling, they fail to reverse the structural damage. PubMed, Google Scholar, and ScienceDirect were searched for all relevant English-language publications. This review synthesizes findings from 135 studies published between 2000 and 2025 that investigate nanomaterial-based differentiation of mesenchymal stem cells (MSCs). MSCs have been recognized as an excellent cell source for regenerative medicine due to their remarkable characteristics. Accumulating evidence suggests that integrating stem cells with nanomaterials opens a new avenue for tissue repair and regeneration and could significantly influence stem cell fate. Integrating stem cells with nanomaterials introduces a paradigm shift from passive cell carriers to bio-instructive systems, in which the nanostructure directly activates osteogenic signaling pathways, leading to enhanced osteogenesis independent of osteogenic factors. Moreover, it discusses the therapeutic potential of osteoblast transplantation in both preclinical and clinical trials for managing bone defects, including osteoporosis. Osteoblast therapy could offer new insights into the future direction of osteoporosis therapy owing to its specificity and minimal side effects compared to current medication. Despite the promising outcomes in pre-clinical settings, further studies are required to establish the optimal safe dosage and to elucidate the underlying mechanism of action. If proven effective, osteoblast transplantation could be eligible for clinical translation.